AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 61 min read$IRTC

Freeman Sean Clinton sold $114K of IRTC

Freeman Sean Clinton (EVP, Strategy & Corp Devt) sold 918 shares of iRhythm Holdings, Inc. (IRTC) at $124.71 ($0.11M total) on 2026-07-02.

Original reporting
SEC EDGAR · Freeman Sean Clinton
Published Jul 6, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale: 918 shares at $124.71 on 2026-07-02, with post-sale holdings of 13,641 shares and no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may monitor for patterns of insider selling, but this single transaction lacks fundamental catalysts.

03

What to watch

Insider sales often reflect liquidity needs, tax planning, or diversification; without additional context (e.g., total insider activity, prior grants, or large-scale selling), signal quality is limited.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-06 after-hours; reflects sale executed 2026-07-02.

Background

The article is a primary-source SEC Form 4 insider transaction for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

IRTC disclosed an EVP Strategy & Corp Development open-market sale of 918 shares at $124.71 on 2026-07-02 via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a Form 4 insider transaction (not a guidance/earnings/regulatory event). The disclosed sale size is modest relative to typical market impact, and no new company-specific operational information is provided.

Market effects

Sector

No clear sector read-through; this is company-specific insider dealing.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a stated 10b5-1 plan could be interpreted as discretionary selling rather than scheduled diversification, but the article provides no motive.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction; EVP sold shares via open-market sale.

  • insider
    Freeman Sean Clinton

    EVP, Strategy & Corporate Development; reported open-market sale of 918 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min
SEP 22
$IRTCMedAI 8/10

IRhythm Holdings, Inc., a Delaware corporation, iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer

SEC EDGAR 8-K1 min